Handbook of Dialysis Therapy Sixth Edition (6th ed/6e)
Edited and written by top experts and pioneers in dialysis, Handbook of Dialysis Therapy, 6th Edition, provides the entire dialysis team with a comprehensive overview of this growing field. It covers traditional and advanced procedures, what pitfalls to expect and how to overcome them, and how best to treat various patient populations—all with a practical approach that can be directly applied to patient care. This must-have resource has been updated with the latest cutting-edge technology, dialysis techniques, and complications related to various diseases for both pediatric and adult patients.
- Explains complex dialysis concepts through abundant diagrams, photos, line drawings, and tables, while its readable, hands-on approach allows for quick review of key information.
- Covers both adult and pediatric patients in detail, and offers guidance on special populations such as the geriatric patients and the chronically ill.
- Features increased content on home-based dialysis modalities, new alternatives for establishing vascular access for hemodialysis, new protocols for reducing the risk of infection and complications, and advancements in establishing and managing peritoneal dialysis.
- Includes extensive pediatric content such as prevention and treatment of bone disease, management of anemia, assessing quality of life in pediatric patients undergoing dialysis, and immunizations in children undergoing dialysis.
- Defines the quality imperatives, roles, and responsibilities of dialysis facility medical directors and attending nephrologists.
- Updates nephrologists on the latest alternative dialysis modalities.
ReviewComprehensive, practical guidance for every member of the dialysis team --This text refers to the paperback edition.
About the AuthorDr. Richard E. Fine received his Bachelor’s and PhD degrees in Biochemistry from University of California at Berkeley and Brandeis University respectively. He then was a postdoctoral fellow in the laboratory of Francis Crick and Sydney Brenner at the Laboratory of Molecular Biology in Cambridge, U.K. During this period he and his colleague, Dennis Bray provided the first evidence for actin in growing neurons. Dr. Fine became an Assistant Professor of Physiology and Biochemistry at Boston University School of Medicine and demonstrated the existence of actin regulatory molecules, tropomyosin and troponin C in growing neurons, and he subsequently became interested in the role of clathrin coated vesicles in endocytic and exocytic processes in neurons and in other tissues. He also isolated and characterized vasopressin receptors, demonstrated for the first time that a large molecular, transferrin, can cross the blood brain barrier. Our lab in collaboration with Dr. Ken Kosik were the first to show that an antisense oligonucleotide can be used in vivo to block the synthesis of a single protein. Using the rabbit retina we were able to show that an antisense nucleotide against the kinesin mRNA can block the critical role of kinesin in the transport of synaptic vesicles, neuropeptide containing vesicles and vesicles destined for the plasma membrane. In recent years Dr. Fine’s laboratory has focused on the role of the amyloid beta peptide in Alzheimer’s disease especially in brain capillary endothelium. Also he has recently focused on the role of a mutant protein VPS35, a component of the retromer in Parkinson’s and Alzheimer’s diseases. During his career he has received over $25,000,000 in grant funding, have served on both NIH and VA review panels and authored or co-authored over 100 research papers. --This text refers to the paperback edition.